| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Eur J Cardiothorac Surg 2001;20:391-398
© 2001 Elsevier Science NL
ski
ulawskiDepartment of Lung and Thoracic Tumors, The Maria Sklodowska–Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
Received 20 November 2000; received in revised form 25 April 2001; accepted 4 May 2001.
Corresponding author. P.O. Box 106, 5 W.K. Roentgen Strasse, 02-770 Warsaw 130, Poland. Tel.: +48-22-644-5554, ext. 2732; fax: +48-22-644-7625
e-mail: gosiap{at}coi.waw.pl
Objectives: To define the place for surgery in combined modality treatment of small cell lung cancer patients. The endpoint was: does complete resection reduce the risk of local failure? Methods: Between November 1981 and June 1996, 75 patients in stage I–III A, many of them with a bulky cN2 tumor at presentation, were exposed to VP-16 based cytoreductive chemotherapy. After three courses of induction treatment, 46 patients underwent thoracotomy and 35 of them had resection. Results: There were two sudden deaths (pulmonary embolism). No other complications were observed. In six cases (6/35=16%), no residual tumor was found in the resected specimen. Four weeks after surgery, chemotherapy was resumed. Three patients experienced local relapse (3/33), among them, the single patient with incomplete resection, and two other patients developed local and distant failure (2/33). Thus, the local relapse rate was 15% (5/33). Eight patients, mainly with chemotherapy induced surgicopathological complete remission (pCR) and with lymph nodes free of tumor in surgical specimens (pN0), are alive, tumor-free, at a median of 136+ months. Two patients died tumor-free at 65 and 147 months. One patient died of unrelated causes at 21 months with no evidence of disease at autopsy. The median survival in the cN0+N1 subsets was 25.09 months, whereas in cN2 disease, this was 13.75 months. There were no long-term survivors among the patients with persistent N2 disease. The median survival in all 35 patients using the Kaplan–Meier method was 18 months; the 5-year tumor-free survival rate was 29% and the 10-year tumor-free survival rate was 23%. Conclusions: Satisfactory local tumor control confirmed the assumption of the study. No residual tumor in the resected specimen (pCR) is the most favorable prognostic factor and determinant of long-term survival. Surgery should not be performed in the patients with persistent N2 disease.
Key Words: Small cell lung cancer • Stage I–III A • Neoadjuvant cytoreductive chemotherapy
This article has been cited by other articles:
|
|
 |
|
  A. Granetzny, A. Boseila, W. Wagner, G. Krukemeyer, U. Vogt, E. Hecker, O. M. Koch, and F. Klinke Surgery in the tri-modality treatment of small cell lung cancer. Stage-dependent survival. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 212 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Badzio, K. Kurowski, H. Karnicka-Mlodkowska, and J. Jassem A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2004; 26(1): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
